ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 658

Elevated 8-Isoprostane In Scleroderma: Implications Of Its Role In Inhibiting Vascular Endothelial Growth Factor-Induced Angiogenesis

Pei-Suen Tsou1, George Zakhem2, Beatrix Balogh2, M. Asif Amin3, Phillip Campbell4, Gautam Edhayan1, Ray Ohara2, Elena Schiopu5, Dinesh Khanna6, Alisa E. Koch3,7 and David A. Fox1, 1Internal Medicine, Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 2University of Michigan Medical School, Ann Arbor, MI, 3Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, 4Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, 5Rheumatology/Internal Medicine, University of Michigan Medical School, Ann Arbor, MI, 6Division of Rheumatology, University of Michigan, Ann Arbor, MI, 7Department of Veteran's Affairs and University of Michigan, Ann Arbor, MI

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Angiogenesis, endothelial cells and scleroderma

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's I

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Scleroderma (SSc) is a complex disease characterized by inflammation, vasculopathy, and excessive disposition of extracellular matrix. Various studies have demonstrated a paradoxical increase in angiogenic mediators, such as vascular endothelial growth factor (VEGF), in both the skin and serum of patients with SSc. Despite this, angiogenesis does not occur normally. The signaling of the thromboxane A2 receptor (TXAR), which can be activated by 8-isoprostane (8-IP), has been shown to inhibit angiogenesis as well as VEGF-induced endothelial cell (EC) differentiation and migration. However, its role in SSc has not been examined. In this study we examined whether 8-IP was elevated in patient plasma and conditioned medium (CM) from ECs, and examined its’ effect on VEGF-induced angiogenesis in SSc.

Methods:

Dermal ECs were isolated from punch biopsies from healthy subjects or patients with diffuse cutaneous SSc. Angiogenesis was assessed by chemotaxis and in vitroMatrigel tube formation assays. 

Results:

SSc patients had significantly higher 8-IP plasma levels (60.9±8.4 pg/ml) compared to healthy subjects (24.9±5.0 pg/ml, p<0.05). When divided into disease subtypes, patients with diffuse SSc or interstitial lung disease showed elevated 8-IP, while those with limited SSc or pulmonary hypertension did not. Increased oxidative stress was detected in SSc ECs as increased 8-IP in SSc EC CM was observed (15.1±2.8 vs. 27.8±3.6 pg/ml, p<0.05). To test whether the increased 8-IP levels in CM affected angiogenesis, we performed Matrigel tube formation assay using NL ECs. SSc EC CM decreased VEGF-induced tube formation in NL ECs while addition of vitamin E restored it. In addition, 8-IP inhibited VEGF-induced healthy EC migration, and the inhibition of TXAR or ROCK pathways restored VEGF-induced angiogenesis inhibited by 8-IP. We then measured ROCK activity in NL and SSc ECs before and after VEGF or 8-IP stimulation. Basal ROCK activity was significantly higher in SSc ECs compared to healthy ECs. 8-IP-induced ROCK activation was significantly higher in SSc ECs while VEGF induced significantly higher ROCK activation in healthy ECs. 

Conclusion:

We show that 8-IP inhibits VEGF-induced migration in healthy ECs through the TXAR/ROCK pathway. SSc ECs produce high levels of 8-IP and exhibit elevated ROCK activity compared to healthy ECs, suggesting that this pathway plays a crucial role in impaired angiogenesis in SSc. This is supported by using vitamin E, which decreases 8-IP, in the Matrigel in vitro assay, in which it restores the inhibitory effect of SSc EC CM on VEGF-induced angiogenesis in healthy ECs. This study provides a potential link between oxidative stress and impaired angiogenesis in SSc, and shows that 8-IP is not just a by-product as a result of oxidative stress, rather it plays a significant role in impaired angiogenesis that characterizes SSc.


Disclosure:

P. S. Tsou,

Arthritis Foundation,

2;

G. Zakhem,
None;

B. Balogh,
None;

M. A. Amin,
None;

P. Campbell,
None;

G. Edhayan,
None;

R. Ohara,
None;

E. Schiopu,
None;

D. Khanna,

NIH,

2;

A. E. Koch,

Eli Lilly and Company,

3;

D. A. Fox,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-8-isoprostane-in-scleroderma-implications-of-its-role-in-inhibiting-vascular-endothelial-growth-factor-induced-angiogenesis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology